PTN Overview

Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin receptor (MCR) system. The MCR system has effects on inflammation and immune system response, food intake, metabolism, and sexual function. Its product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical need and commercial potential. Its product development activities focus primarily on the use of MC4R agonists for treatment of obesity. It develops MC4R peptides and small molecule agonists with potential utility in obesity and metabolic-related disorders, rare MC4R pathway diseases, such as hypothalamic obesity, and orphan indications. It also develops MC1R agonist products to treat inflammatory and autoimmune diseases, such as dry eye disease, which is also known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease.

Wall Street analysts forecast PTN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PTN is50.00 USD with a low forecast of 50.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Palatin Technologies Inc revenue for the last quarter amounts to 116.04K USD, decreased

Palatin Technologies Inc. EPS for the last quarter amounts to -2.86 USD, decreased -51.69

Palatin Technologies Inc (PTN) has 29 emplpoyees as of April 20 2026.

Today PTN has the market capitalization of 39.87M USD.